UNSPSC 51112029: Nintedanib

Nintedanib is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

UNSPSC 51112029 Nintedanib is a Commodity-tier code representing pharmaceutical products procured by state and local health systems, fire departments, emergency medical services, and forensic laboratories. State and local governments buy nintedanib and similar specialty pharmaceuticals as part of broader medical supply contracts, emergency response inventories, and clinical pharmacy programs, though recent solicitations tagged under this code show minimal direct procurement activity specific to nintedanib alone. The issuing bodies soliciting under related pharmaceutical codes include county health departments, municipal fire and EMS agencies, and specialty forensic laboratories, with activity concentrated in Florida, Arizona, and Minnesota through both direct purchase and cooperative purchasing arrangements. When pharmaceutical codes are solicited, they typically appear within larger multi-item medical supply, emergency response, or clinical services RFPs rather than as standalone commodity procurements.

Recent opportunities tagged under pharmaceutical UNSPSC codes show limited activity directly matching nintedanib specifications. The most relevant recent solicitations include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems; the City of Tucson Fire Department's RFP 260217 (posted June 24, 2026, due June 24, 2026) for BLS and ALS pharmaceuticals and supplies with 251 line items through VendNovation vending systems; and Pinellas County, Florida's ITQ 26-0305-ITQ (posted April 23, 2026, due April 23, 2026) for certified drug standards for forensic laboratory analysis. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon through authorized wholesalers, with a two-year contract term and 3 percent administrative fee structure. These solicitations emphasize compliance with cGMP, FDA requirements, DEA licensing where applicable, and Drug Supply Chain Security Act standards, with pricing weighted at 75 percent in MMCAP's evaluation criteria.